IceCure Medical Ltd. (ICCM) Q1 2026 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Icecure Medical Ltd..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:02.673 Good morning, and thank you for standing by. 00:00:02.673 -- 00:00:06.317 Currently, all of the participants are in listen-only mode. 00:00:06.317 -- 00:00:10.560 After management discussion, there will be a question-and-answer session. 00:00:10.560 -- 00:00:14.284 Please be advised that today's conference call is being recorded. 00:00:14.284 -- 00:00:17.967 I would now like to turn the conference over to Michael Polyview. 00:00:17.967 -- 00:00:19.849 Please go ahead. 00:00:19.849 -- 00:00:24.333 Thank you, Operator, and welcome to IceCure Medical's conference call to review the financial 00:00:24.333 -- 00:00:29.647 results as of and for the three months ended March 31, 2026. 00:00:29.647 -- 00:00:33.352 and provide an update on recent operational highlights. 00:00:33.352 -- 00:00:37.817 You may refer to the earnings press release that we issued earlier this morning. 00:00:37.817 -- 00:00:43.405 Participating on today's call are Ice Care Medical's CEO, Al Shamir, the company's 00:00:43.405 -- 00:00:47.590 VP of sales, North America, Shad Good, and our guest, Dr. 00:00:47.590 -- 00:00:52.676 Richard Fine, a key opinion leader in the treatment of breast cancer, a breast surgeon, 00:00:52.676 -- 00:00:57.643 and Ice III investigator who has published and presented Ice III data and is active in 00:00:57.643 -- 00:01:02.495 hands-on trainings and symposia for Cryoablation and the Treatment of Early-Stage Breast 00:01:02.495 -- 00:01:07.760 Cancer. Before we begin, I will now take a moment to read a statement about overlooking 00:01:07.760 -- 00:01:12.726 statements. This call and the question and answer section that follows it contains overlooking 00:01:12.726 -- 00:01:17.451 statements within the meaning of the SAPAR provisions of the...